The Southern Medical Journal (SMJ) is the official, peer-reviewed journal of the Southern Medical Association. It has a multidisciplinary and inter-professional focus that covers a broad range of topics relevant to physicians and other healthcare specialists.
SMJ // Article
Original Article
Patient Selection for Drip and Ship Thrombolysis in Acute Ischemic Stroke
Abstract
Objectives: The drip and ship model is a method used to deliver thrombolysis to acute stroke patients in facilities lacking onsite neurology coverage. We sought to determine whether our drip and ship population differs from patients treated directly at our stroke center (direct presenters).Methods: We retrospectively reviewed consecutive patients who received thrombolysis at an outside facility with subsequent transfer to our center between 2009 and 2011. Patients received thrombolysis after telephone consultation with a stroke specialist. We examined demographics, vascular risk factors, laboratory values, and stroke severity in drip and ship patients compared with direct presenters.
Results: Ninety-six patients were identified who received thrombolysis by drip and ship compared with 212 direct presenters. The two groups did not differ with respect to sex, ethnicity, vascular risk factors, or admission glucose. The odds ratio (OR) of arriving at our hospital as a drip and ship for someone 80 years or older was 0.31 (95% confidence interval [CI] 0.15–0.61, P < 0.001). Only 21% of drip and ship patients were black versus 38% of direct presenters (OR 0.434, 95% CI 0.25–0.76, P = 0.004). Even after stratifying by age (<80 vs ≥80), a smaller proportion of drip and ship patients were black (OR 0.44, 95% CI 0.24–0.81, P = 0.008). Furthermore, we found that fewer black patients with severe strokes arrived by drip and ship (OR 0.33, 95% CI 0.11–0.98, P = 0.0028).
Conclusions: Our study showed that a smaller proportion of blacks and older adults arrived at our center by the drip and ship model. This may reflect differences in how patients are selected for thrombolysis and transfer to a higher level of care.
This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rT-PA stroke study group. N Engl J Med 1995;333:1581-1587.
2. Kleindorfer D, Lindsell CJ, Brass L, et al. National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate. Stroke 2008;39:924-928.
3. Reeves MJ, Arora S, Broderick JP, et al. Acute stroke care in the US: results from 4 pilot prototypes of the Paul Coverdell National Acute Stroke Registry. Stroke 2005;36:1232-1240.
4. Adeoye O, Hornung R, Khatri P, et al. Recombinant tissue-type plasminogen activator use for ischemic stroke in the United States: a doubling of treatment rates over the course of 5 years. Stroke 2011;42:1952-1955.
5. Barber PA, Zhang J, Demchuk AM, et al. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 2001;56:1015-1020.
6. Majersik JJ, Meurer WJ, Frederiksen SA, et al. Observational study of telephone consults by stroke experts supporting community tissue plasminogen activator delivery. Acad Emerg Med 2012;19:E1027-E1034.
7. Pervez MA, Silva G, Masrur S, et al. Remote supervision of IV-tPA for acute ischemic stroke by telemedicine or telephone before transfer to a regional stroke center is feasible and safe. Stroke 2010;41:e18-e24.
8. Tekle WG, Chaudhry SA, Hassan AE, et al. Drip-and-ship thrombolytic treatment paradigm among acute ischemic stroke patients in the United States. Stroke 2012;43:1971-1974.
9. Mansoor S, Zand R, Al-Wafai A, et al. Safety of a ‘‘drip and ship’’ intravenous thrombolysis protocol for patients with acute ischemic stroke. J Stroke Cerebrovasc Dis 2013;22:969-971.
10. Qureshi AI, Chaudhry SA, Rodriguez GJ, et al. Outcome of the ‘drip-and-ship’ paradigm among patients with acute ischemic stroke: results of a statewide study. Cerebrovasc Dis Extra 2012;2:1-8.
11. Martin-Schild S, Morales MM, Khaja AM, et al. Is the drip-and-ship approach to delivering thrombolysis for acute ischemic stroke safe? J Emerg Med 2011;41:135-141.
12. Silverman IE, Beland DK, Chhabra J, et al. The ‘‘drip-and-ship’’ approach: starting IV t-PA for acute ischemic stroke at outside hospitals prior to transfer to a regional stroke center. Conn Med 2005;69:613-620.
13. Hsia AW, Edwards DF, Morgenstern LB, et al. Racial disparities in tissue plasminogen activator treatment rate for stroke: a population-based study. Stroke 2011;42:2217-2221.
14. Karve SJ, Balkrishnan R, Mohammad YM, et al. Racial/ethnic disparities in emergency department waiting time for stroke patients in the United States. J Stroke Cerebrovasc Dis 2011;20:30-40.
15. Saver JL, Yafeh B. Confirmation of tPA treatment effect by baseline severity-adjusted end point reanalysis of the NINDS-tPA stroke trials. Stroke 2007;38:414-416.
16. American Community Survey, 2009-2011 American Community Survey 3-Year Estimates. www.nhgis.org. Accessed May 2, 2014.
17. Howard VJ, Acker J, Gomez CR, et al. An approach to coordinate efforts to reduce the public health burden of stroke: The Delta States Stroke Consortium. Prev Chronic Dis 2004;1:A19.
18. US Department of Commerce. State and county QuickFacts. http://quickfacts.census.gov/qfd/states/01000.html. Accessed May 2, 2014.
19. Bender R, Lange S. Adjusting for multiple testing–when and how? J Clin Epidemiol 2001;54:343-349.
20. Siegler JE, Boehme AK, Albright KC, et al. Ethnic disparities trump other risk factors in determining delay to emergency department arrival in acute ischemic stroke. Ethn Dis 2013;23:29-34.
21. Brown RD, Whisnant JP, Sicks JD, et al. Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989. Stroke 1996;27:373-380.
22. Wolf PA, D’Agostino RB, O’Neal MA, et al. Secular trends in stroke incidence and mortality. The Framingham study. Stroke 1992;23:1551-1555.
23. Howard VJ, Lackland DT, Lichtman JH, et al. Care seeking after stroke symptoms. Ann Neurol 2008;63:466-472.
24. Hills NK, Johnston SC. Why are eligible thrombolysis candidates left untreated? Am J Prev Med 2006;31(6 Suppl 2):S210YS216.
25. Longstreth WT Jr, Katz R, Tirschwell DL, et al. Intravenous tissue plasminogen activator and stroke in the elderly. Am J Emerg Med 2010;28:359-363.
26. Centers for Disease Control and Prevention. Prevalence of stroke--United States, 2006-2010. MMWR Morb Mortal Wkly Rep 2012;61:379-382.
27. Zanaty M, Chalouhi N, Starke RM, et al. Epidemiology of a large telestroke cohort in the Delaware Valley. Clin Neurol Neurosurg 2014;125:143-147.
28. Adeoye O, Haverbusch M, Woo D, et al. Is ED disposition associated with intracerebral hemorrhage mortality? Am J Emerg Med 2011;29:391-395.
29. Schwamm LH, Reeves MJ, Pan W, et al. Race/ethnicity, quality of care, and outcomes in ischemic stroke. Circulation 2010;121:1492-1501.
30. Adams R, Acker J, Alberts M, et al. Recommendations for improving the quality of care through stroke centers and systems: an examination of stroke center identification options: multidisciplinary consensus recommendations from the Advisory Working Group on Stroke Center Identification Options of the American Stroke Association. Stroke 2002;33:e1-e7.
